NCT05993949View on ClinicalTrials.gov

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Lymphoblastic Leukemia
Interventions
DRUG

Dasatinib

3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria

Trial Locations (1)

94305

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Kite, A Gilead Company

INDUSTRY

lead

Stanford University

OTHER

NCT05993949 - Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter